surmount-1 tirzepatide 15 mg weight loss percent (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants REDEFINE 4 vs SURMOUNT: how
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3





![Ozempic Blood Clots Lawsuit [2026 Update]](https://www.robertkinglawfirm.com/wp-content/uploads/2024/08/how-does-ozempic-cause-blood-clots.webp)
![Wegovy Blood Clots Lawsuit [2026 Update]](https://www.robertkinglawfirm.com/wp-content/uploads/2024/09/does-wegovy-cause-blood-clots.webp)
![Can Ozempic Cause Blood Clots? [2026 Update]](https://www.robertkinglawfirm.com/wp-content/uploads/2024/08/ozempic-blood-clots-deep-vein-thrombosis-pulmonary-embolism.webp)




















